• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 14, 2020

View Archived Issues
Person receiving vaccine

Carry on studying: Astrazeneca-Oxford COVID-19 vaccine trial resumes

The Astrazeneca plc and Oxford University phase III trial of their adenovirus-based coronavirus vaccine is back up and running in the U.K. after a week’s worth of study and decision-making. The company said it still plans to report data from the study by the end of this year. Read More

$21B acquisition of Immunomedics strengthens Gilead’s oncology portfolio

In the company’s largest acquisition and potentially the fifth biggest biotech M&A ever, Gilead Sciences Inc. will acquire Immunomedics Inc. for $21 billion in a move that substantially transforms Gilead’s oncology portfolio. Read More
Deal-handshake-graphic-overlay

Dealer’s choice: Further Seagen BD in cards as Merck on button, makes whopper bet

Though falling short of the outright takeover that some may have hoped for, Merck & Co. Inc.’s dual tie-ups with Seattle Genetics Inc. (Seagen) put the latter in solid position to shop for acquisitions of its own. Read More
Financings-coins-stock-chart.png

Neogene’s $110M series A for individualized TCR approach in cancer

LONDON – Neogene Therapeutics BV has raised $110 million in a series A round to advance development of a novel T-cell immunotherapy for treating solid tumors. Read More

Cassava turns bitter phase IIb readout sweet with updated biomarker data

A new analysis of biomarkers, superseding confusing results released in May, appears to have re-ignited enthusiasm for the experimental Alzheimer’s disease (AD) candidate, sumifilam, the lead development candidate at Texas-based Cassava Sciences Inc. Read More

Charmless: Third CRL for Mallinckrodt’s terlipressin

Mallinckrodt plc’s decade-long frustration with getting approval for its vasopressin analogue selective for V1 receptors, terlipressin, for use in hepatorenal syndrome type 1 continues as the FDA issued the company a third complete response letter (CRL) for the drug. Read More
AI-network-machine-learning.png

Biopharma companies utilizing artificial intelligence for drug research

The BioWorld Artificial Intelligence price-weighted index, which includes biopharmaceutical companies, medical devices and health care services companies, has climbed in value and is currently up almost 37% year-to-date. Read More

Valneva inks $1.7B U.K. deal for COVID-19 vaccine; Regeneron’s REGN-COV2 joins Recovery trial

LONDON – The U.K. government has signed a €1.4 billion (US$1.7 billion) advance purchase agreement with French biotech Valneva SE, for the supply of up to 190 million doses of its attenuated COVID-19 vaccine, VLA-2001. Read More
Astrocytes

Astrocytes, ‘star cells,’ are stealing the show in neuropsychopharmacology

In brain research, neurons have long been the stars of the show. But that status is in part because they are flashiest. Read More

Australia’s Clinuvel expands R&D presence as it builds out pipeline for DNA repair

PERTH, Australia – With the launch of its lead product, Scenesse (afamelanotide), in the U.S. and Europe, Melbourne-based Clinuvel Pharmaceuticals Ltd. is expanding its global footprint and widening its pipeline as it opens a new R&D center in Singapore and builds up its franchise in photo medicine. Read More
Drug-prices_money_calculator_pills

‘Most-favored nation’ pricing: Empty gesture? Or a sign of things to come?

Ignoring industry’s threat of a lawsuit, U.S. President Donald Trump is moving forward with his plan for “most-favored nation” pricing of certain prescription drugs. The president, on Sept. 13, signed the executive order he threatened in July if industry didn’t come up with a better offer by Aug. 24. Industry did make a counter offer last month, but apparently it wasn’t enough. Read More

Canbridge wins approval for MPS II drug and expands partnership with UMass

BEIJING – Canbridge Pharmaceuticals Inc. last week won marketing approval in China for its first rare disease drug, the mucopolysaccharidosis II therapy Hunterase (idursulfase beta injection). Read More

Celltrion advancing COVID-19 antibody treatment CT-P59 and trials continue

HONG KONG – Interim results of a phase I study CT-P59, an anti-COVID-19 monoclonal antibody being developed by Incheon, South Korea-based Celltrion Inc., have confirmed the candidate’s safety, tolerability and pharmacokinetics in healthy subjects, giving the company confidence to ramp up production of the experimental antiviral. Read More
T cells

Notch4 key to asthma’s T-cell derailment

BioWorld looks at translational medicine. Read More

ICYMI: Week in review, Sept. 8-11, 2020

A quick look back at top stories. Read More

Adcom: ADF offers no meaningful reduction in overall Oxycontin abuse

The latest global regulatory news, changes and updates affecting biopharma, including: FDA advises on getting back to business as usual; ICER evidence report targets ulcerative colitis treatments. Read More

Appointments and advancements for Sept. 14, 2020

New hires and promotions in the biopharma industry, including: Eloxx, Enosi, Eqrx, Silence, Starton, Synlogic, Vyne. Read More

Financings for Sept. 14, 2020

Biopharmas raising money in public or private financings, including: Athira, Attralus, Atyr, Compass, Escape, Escient, Painreform, Resolution, Syncona. Read More

In the clinic for Sept. 14, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, AB Science, Actinium, Alexion, Alzprotect, Astrazeneca, Biontech, Blade, Boehringer, Caelum, Cassava, Celltrion, Cyxone, Daiichi, Diamedica, Diamyd, Enanta, Frequency, Humanigen, Immunity, Incyte, Inflarx, LB, Lilly, Myovant, Novartis, Pfizer, Pharmabcine, Regeneron. Read More

Other news to note for Sept. 14, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ABL, Accord, Acelrx, Aimmune, Arctoris, Astrazeneca, Biogen, Daiichi Sankyo, Evotec, Glycot, Hifibio, J&J, Keros, Lava, Marinus, Medigen, Molecular Partners, Moleculin, Molteni, Navire, Navrogen, Nestle, Neuraxpharm, Orexo, Pascal, Pfizer, Reveragen, Santhera, Sorrento, S?rse, Springworks, Starpharma, Syntekabio Takeda, Talaris, Tikomed, Vaxess. Read More

Regulatory actions for Sept. 14, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascentage, Cycle, Essa, Gan & Lee, Gannex, Kiadis, Mateon, Novartis, Pharmacyte, Regeneron, Reven, Sanofi, SK, Seneca, Supernus, Vaxart, Vertex, Ziopharm. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    BioWorld Science
    Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe